Contributions of Rad9 to tumorigenesis

被引:32
作者
Broustas, Constantinos G. [1 ]
Lieberman, Howard B. [1 ,2 ]
机构
[1] Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA
[2] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA
基金
美国国家卫生研究院;
关键词
Rad9; ONCOGENE; TUMOR SUPPRESSOR; CELL CYCLE CHECKPOINT; DNA REPAIR; HUMAN CHECKPOINT SENSOR; PROSTATE-CANCER CELLS; DNA-DAMAGE RESPONSE; EXCISION-REPAIR; RAD9-RAD1-HUS1; INTERACTS; MULTIPLE CHECKPOINT; 11Q13; AMPLIFICATION; TUMOR-SUPPRESSOR; POLYMERASE-BETA; PROTEIN HRAD9;
D O I
10.1002/jcb.23424
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Rad9 plays a crucial role in maintaining genomic stability by regulating cell cycle checkpoints, DNA repair, telomere stability, and apoptosis. Rad9 controls these processes mainly as part of the heterotrimeric 9-1-1 (Rad9-Hus1-Rad1) complex. However, in recent years it has been demonstrated that Rad9 can also act independently of the 9-1-1 complex as a transcriptional factor, participate in immunoglobulin class switch recombination, and show 3'-5' exonuclease activity. Aberrant Rad9 expression has been associated with prostate, breast, lung, skin, thyroid, and gastric cancers. High expression of Rad9 is causally related to, at least, human prostate cancer growth. On the other hand, deletion of Mrad9, the mouse homolog, is responsible for increased skin cancer incidence. These results reveal that Rad9 can act as an oncogene or tumor suppressor. Which of the many functions of Rad9 are causally related to initiation and progression of tumorigenesis and the mechanistic details by which Rad9 induces or suppresses tumorigenesis are presently not known, but are crucial for the development of targeted therapeutic interventions. J. Cell. Biochem. 113: 742751, 2012. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:742 / 751
页数:10
相关论文
共 99 条
[1]   Rad9 Is Required for B Cell Proliferation and Immunoglobulin Class Switch Recombination [J].
An, Lili ;
Wang, Yulan ;
Liu, Yuheng ;
Yang, Xiao ;
Liu, Chunchun ;
Hu, Zhishang ;
He, Wei ;
Song, Wenxia ;
Hang, Haiying .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (46) :35267-35273
[2]   Interaction between human mismatch repair recognition proteins and checkpoint sensor Rad9-Rad1-Hus1 [J].
Bai, Haibo ;
Madabushi, Amrita ;
Guan, Xin ;
Lu, A-Lien .
DNA REPAIR, 2010, 9 (05) :478-487
[3]   Long Patch Base Excision Repair Proceeds via Coordinated Stimulation of the Multienzyme DNA Repair Complex [J].
Balakrishnan, Lata ;
Brandt, Patrick D. ;
Lindsey-Boltz, Laura A. ;
Sancar, Aziz ;
Bambara, Robert A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (22) :15158-15172
[4]   Disruption of the Rad9/Rad1/Hus1 (9-1-1) complex leads to checkpoint signaling and replication defects [J].
Bao, SL ;
Lu, T ;
Wang, X ;
Zheng, HY ;
Wang, LE ;
Wei, QY ;
Hittelman, WN ;
Li, L .
ONCOGENE, 2004, 23 (33) :5586-5593
[5]   Human DNA damage checkpoint protein hRAD9 is a 3′ to 5′ exonuclease [J].
Bessho, T ;
Sancar, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (11) :7451-7454
[6]   Targeted Knockdown of Notch1 Inhibits Invasion of Human Prostate Cancer Cells Concomitant with Inhibition of Matrix Metalloproteinase-9 and Urokinase Plasminogen Activator [J].
Bin Hafeez, Bilal ;
Adhami, Vaqar Mustafa ;
Asim, Mohammad ;
Siddiqui, Imtiaz A. ;
Bhat, Kumar M. ;
Zhong, Weixiong ;
Saleem, Mohammad ;
Din, Maria ;
Setaluri, Vijayasaradhi ;
Mukhtar, Hasan .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :452-459
[7]  
Cai RL, 2000, J BIOL CHEM, V275, P27909
[8]   Localization of hRad9 in breast cancer [J].
Chan, Vivian ;
Khoo, U. S. ;
Wong, M. S. ;
Lau, Ken ;
Suen, Dacita ;
Li, George ;
Kwong, Ava ;
Chan, T. K. .
BMC CANCER, 2008, 8 (1)
[9]   Interaction of checkpoint proteins Hus1/Rad1/Rad9 with DNA base excision repair enzyme MutY homolog in fission yeast, Schizosaccharomyces pombe [J].
Chang, DY ;
Lu, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (01) :408-417
[10]   NF-κB addiction and its role in cancer: 'one size does not fit all' [J].
Chaturvedi, M. M. ;
Sung, B. ;
Yadav, V. R. ;
Kannappan, R. ;
Aggarwal, B. B. .
ONCOGENE, 2011, 30 (14) :1615-1630